Fig. 1: Development of a chemo- and immune-checkpoint-resistant MIBC model, with a T-cell-non-inflamed phenotype. | Nature Communications

Fig. 1: Development of a chemo- and immune-checkpoint-resistant MIBC model, with a T-cell-non-inflamed phenotype.

From: Cell death-induced immunogenicity enhances chemoimmunotherapeutic response by converting immune-excluded into T-cell inflamed bladder tumors

Fig. 1

a Schematic for establishment of muscle-invasive bladder cancer syngeneic lines. b Immunofluorescence analysis of CD3+ T-cell infiltration and aSMA expression in G69 treatment-naïve tumor tissues (Scale bar: 100 μm; Images representative of n = 3 independent experiments). c Relative localization of CD3+ T cells in treatment naïve G69 tumors. CD3+ T cells in regions of interest were quantified and normalized to average CD3+ T-cell infiltration (n = 9 biologically independent samples). Data are presented as mean values ± SEM. (**—Two-tailed, unpaired t-test p = 0.0045) d, e Weight and growth curve of G69 tumors treated with vehicle (n = 8 biologically independent animals) or gemcitabine (120 mg/kg) and cisplatin (6 mg/kg) (n = 10 biologically independent animals) for two cycles. Data are presented as mean values ± SEM. (Two-tailed, unpaired t-test at endpoint values). f Growth curve of vehicle (n = 8 biologically independent animals) or anti-PD1-treated (n = 3 biologically independent animals) (200 mg/mouse) G69 tumors monitored for 21 days. Data are presented as mean values ± SEM. (Two-tailed, unpaired t-test at endpoint values). Source data are provided as a Source data file. ns: not significant.

Back to article page